COVID-19 Diagnostic and Screening Tests
Enabling the detection of the novel coronavirus SARS-CoV-2 through diagnostic and screening tests.
We use first and third party cookies to enable the browsing through the website and to improve the services by analyzing your browsing habits. If you continue browsing the website, you accept its installation and use as aforementioned. You may modify the settings and obtain more information here
Since the pandemic began, Grifols has made its expertise in plasma available to health authorities, governments, regulatory agencies, and society in general. At Grifols, we believe this current and extraordinary situation requires healthcare companies like ours to strive further to serve patients and society.
For over a century, Grifols has been a healthcare company at the vanguard of blood- and plasma-therapy development, with the aim of enhancing people's health and well-being.
At Grifols, we believe in the therapeutic potential of human plasma and its components. During this unprecedented health crisis, plasma from patients who have recovered from COVID-19, called convalescent plasma, has been identified as a therapeutic option that can potentially help combat the disease.
This plasma from recovered COVID-19 donors contains antibodies which are specific against SARS-CoV-2, the virus that causes COVID-19. These antibodies are proteins called immunoglobulins, which may help the body fight this infectious disease.
Convalescent plasma is currently being investigated to be used:
Grifols has been applying its broad knowledge and deep expertise in producing immunoglobulins to manufacture a specific anti-SARS-CoV-2 hyperimmune globulin to combat two different stages of COVID-19 disease: hospitalized patients and asymptomatic outpatients.
The clinical trial evaluating the safety, efficacy and tolerability of the intravenously administered anti-SARS-CoV-2 hyperimmune globulin in hospitalized patients started in October 2020. It's the first international multicenter clinical trial of an immunoglobulin containing anti-SARS-CoV-2 polyclonal antibodies from plasma donors who have recovered from the illness. The trial, which will include 500 hospitalized adults with COVID-19 in up to 58 hospitals covering 18 countries, is sponsored and funded by the National Institute of Allergy and Infectious Diseases (NIAID), part of the U.S. National Institutes of Health (NIH).
In February, a study will start in Spain with 800 asymptomatic SARS-CoV-2-positive patients who will receive the immunoglobulin subcutaneously on an outpatient basis. This trial will be led by the researchers Oriol Mitjà and Bonaventura Clotet from Germans Trias i Pujol Hospital in Badalona (Barcelona).
In addition to the hyperimmune globulin, Grifols is also carrying out several clinical trials to evaluate the safety and efficacy of convalescent plasma for direct transfusion. On August 23, 2020, the FDA gave emergency use authorization (EUA) for convalescent plasma to treat hospitalized COVID-19 patients.
Grifols is collecting plasma from recovered COVID-19 patients using its network of more than 300 donor centers in the U.S. and Germany, the largest global network of donation centers in the world. Our experienced technicians are specially trained and prepared to help our donors, whose generous and compassionate contributions enable us to develop potential treatments. Grifols is also collecting convalescent plasma in Spain through a collaboration with blood banks.
We're also proud to be part of a coalition of world-class medical and research institutions, blood centers, life-science companies, philanthropic organizations and COVID-19 survivor groups that has come together to mobilize tens of thousands of people in the United States who have recovered from COVID-19 to donate their plasma. Visit TheFightIsInUs.org.
Trialing an anti-SARS-CoV-2 hyperimmune globulin and convalescent plasma as a direct transfusion therapy, and evaluating the potential efficacy of currently available plasma-derived therapies.
Enabling the detection of the novel coronavirus SARS-CoV-2 through diagnostic and screening tests.
Supporting external research, such as GigaGen's, recombinant polyclonal antibodies therapy or the initiative led by the Catalan consortium –including IrsiCaixa, Barcelona Supercomputing Center (BSC) and the Animal Health Research Center (CReSA) at the Institute for Food and Agricultural Research and Technology (IRTA)– to discover vaccine prototypes and antibody therapeutics for SARS-CoV-2.
Organizing food drives to aid communities and providing donations of personal protection equipment to the areas most impacted by the pandemic. In addition, technical and logistical support to hospitals for the storage, preparation and dispensing of medicines, as well as the refurbishment and expansion of facilities to treat COVID-19 patients.
Up-to-date Press Releases, News, Statements and Media Coverage throughout the COVID-19 pandemic.
The information contained on the Grifols worldwide website is not applicable to all countries. For specific information on the products and services available in your country, please select your country from the list included in the corresponding section. The purpose of this website is to provide information about Grifols' products and services, and it is not intended for, nor may it be construed to, promoting any products in countries in which they are not approved.
This website uses its own and third party essential (to remember your settings) and non-essential (to analyse our traffic) cookies. Further information about our use of cookies and the third parties using them can be found in our Cookies Policy.
You can accept all non-essential cookies by clicking the "Accept" button, reject their use by clicking the "Refuse" button or set your preferencies by clicking the "Settings" link.
You can withdraw or change your cookies consent at any time by visiting our Cookies Policy.
Essential cookies
These are strictly necessary for the Site to work as requested. Some examples are activating basic functions such as page navigation and access to secure Site areas or customizing the Site presentation (e.g. language). Without these cookies, the Site would not be able to work properly.
By clicking below you consent to the use of the following non-essential cookies:
Analytic cookies
These allow understanding how visitors interact with the Site by monitoring and analyzing your behavior and with the purpose of improving the Site.